Navigation Links
Cornerstone Therapeutics to Present at BioCentury's 2009 Future Leaders in the Biotech Industry Conference
Date:3/31/2009

CARY, N.C., March 31 /PRNewswire-FirstCall/ -- Cornerstone Therapeutics Inc. (Nasdaq: CRTX), a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory market, today announced that Craig A. Collard, President and Chief Executive Officer, will be presenting a corporate overview at BioCentury's 16th Annual Future Leaders in the Biotech Industry Conference at 2:00 PM EDT on Thursday, April 2, 2009, at the Millennium Broadway Hotel & Conference Center in New York City.

A live audio and archived webcast of Cornerstone's presentation will be available through the Investor Relations section of the Company's website.

About Cornerstone Therapeutics

Cornerstone Therapeutics Inc. (Nasdaq: CRTX), headquartered in Cary, N.C., is a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory market. The Company currently promotes multiple marketed products in the United States to respiratory-focused physicians and key retail pharmacies with its specialty sales force. The Company also has a late-stage clinical pipeline with five regulatory approval submissions targeted within the next three years. Key elements of the Company's strategy are to in-license or acquire rights to underpromoted, patent-protected, branded respiratory pharmaceutical products, or late-stage product candidates; implement life cycle management strategies to maximize the potential value and competitive position of the Company's currently marketed products, newly acquired products and product candidates that are currently in development; grow product revenue through the Company's specialty sales force which is focused on the respiratory market; and maintain and strengthen the intellectual property position of the Company's currently marketed products, newly acquired products and product candidates.

    Investor Relations Contacts:
    FD
    Evan Smith/Brian Ritchie
    212-850-5600
    evan.smith@fd.com/brian.ritchie@fd.com

    Media Relations Contact:
    FD
    Robert Stanislaro
    212-850-5600
    robert.stanislaro@fd.com


'/>"/>
SOURCE Cornerstone Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results
2. Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call
3. Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance
4. Arno Therapeutics Reports 2008 Year-End Financial Results
5. Stockholder Suits Related to TorreyPines Therapeutics, Inc. Dismissed
6. Webcast Alert: Oxygen Biotherapeutics, Inc. Investor Meeting in Zurich, Switzerland
7. Frost & Sullivan Hosts Presentation on MicroRNAs: From Stem Cells and Cancer to Diagnostics and Therapeutics
8. Amicus Therapeutics to Present at the 16th Annual Future Leaders in the Biotech Industry Conference
9. Amicus Therapeutics Presents Positive Results From Phase 2 Extension Study of Amigal(TM) for Fabry Disease at ACMG 2009 Annual Meeting
10. Nile Therapeutics Provides Update on Phase II CD-NP Clinical Trial for Acute Heart Failure
11. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... ... 28, 2017 , ... RoviSys, a leading independent provider of ... joined the Cisco® Digital Solutions Integrator Program. As a member of this new ... addresses Industrial IT and Business IT in manufacturing environments. , John Cunningham, ...
(Date:2/28/2017)... ... February 28, 2017 , ... LaunchBio, a ... biotechnology companies today announced it named Joan Siefert Rose as CEO. Rose, ... Durham, NC and will begin work immediately. , Rose most recently served as ...
(Date:2/28/2017)... NEW YORK , February 28, 2017 /PRNewswire/ ... by the FDA for avelumab  Prognosis for urothelial ...   EMD Serono, the ... , in the US and Canada , ... Drug Administration (FDA) has accepted for Priority Review EMD Serono,s ...
(Date:2/27/2017)... Calif. , Feb. 27, 2017 ... company focused on the development and commercialization of ... pain, announced today the U.S. Food and Drug ... Application (NDA) under section 505(b)(2) for DSUVIA™ (formerly ... treatment of patients with moderate-to-severe acute pain in ...
Breaking Biology Technology:
(Date:2/2/2017)... Feb. 2, 2017  EyeLock LLC, a market leader ... white paper " What You Should Know About Biometrics ... ensuring user authenticity is a growing concern. In traditional ... users. However, traditional authentication schemes such as username/password suffer ... Biometric authentication offers an elegant solution to the problem ...
(Date:2/1/2017)... , February 1, 2017 IDTechEx Research, ... on emerging technology, announces the availability of a new report, ... Continue Reading ... ... industrial and collaborative robots. Source: IDTechEx Report "Sensors for Robotics: Technologies, ...
(Date:1/30/2017)... SAN FRANCISCO , Jan. 30, 2017   ... of the fastest growing genetic information companies, today announced ... 2016 financial results and provide 2017 guidance on Monday, ... a conference call that day at 4:45 p.m. Eastern ... call, Invitae,s management team will briefly review financial results, ...
Breaking Biology News(10 mins):